Bladder cancer
Authors:
- Kirk A KeeganKKKirk A Keegan
- Peter E ClarkPCPeter E Clark
- 1 May 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 23 (3) , 275-282
Abstract
To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year. Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time. Although a number of urinary markers for bladder cancer are now approved by the Food and Drug Administration, there is not enough evidence that any marker can replace surveillance cystoscopy. Management of high-risk patients with nonmuscle-invasive cancer remains a challenge, with continued controversy over which patients may safely be treated with bladder-sparing regimens. Efforts toward developing agents for bacillus Calmette-Guerin-refractory superficial bladder cancer continue, however, none to date have shown high rates of long-term success. In patients undergoing cystectomy, reports using more standardized measures of complications have demonstrated high rates of postoperative morbidity and mortality, particularly in elderly individuals. Robot-assisted radical cystectomy is being more widely studied as a potential approach to decrease operative blood loss and shorten recovery. Although more expensive, increasing evidence suggests that it is well tolerated, does not increase the risk of positive surgical margins, and can achieve similar lymph node counts as open cystectomy in experienced hands and with careful patient selection. Despite level I evidence supporting the use of neoadjuvant chemotherapy, there remains disagreement regarding its use vs. selective adjuvant therapy, given the modest benefits seen with current regimens. Progress continues in bladder cancer diagnosis and management, and we anticipate that future work will further advance the care of patients with this disease.Keywords
This publication has 98 references indexed in Scilit:
- Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancerJournal of Clinical Pathology, 2010
- Prospective Randomized Controlled Trial of Robotic versus Open Radical Cystectomy for Bladder Cancer: Perioperative and Pathologic ResultsEuropean Urology, 2010
- A Comparison of Postoperative Complications in Open versus Robotic CystectomyEuropean Urology, 2010
- A Case–Control Study of Smoking and Bladder Cancer Risk: Emergent Patterns Over TimeJNCI: Journal of the National Cancer Institute, 2009
- Urinary diversion and morbidity after radical cystectomy for bladder cancerCancer, 2009
- Potential new urinary markers in the early detection of bladder cancerCurrent Opinion in Urology, 2009
- Phase 2 trial of sorafenib in patients with advanced urothelial cancerCancer, 2009
- Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?Cancer, 2009
- A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladderCancer, 2008
- Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802)Cancer, 2008